In vitro the inhibition of cyclo oxygenase does not result in an increase in leukotriene formation. The mechanism of the analgesic action of lornoxicam has not been fully determined.
Lornoxicam is absorbed rapidly and almost completely from the gastrointestinal tract.
Maximum plasma concentrations are achieved after approximately 1 to 2 hours.
The absolute bioavailability (calculated on AUC) of XEFO film-coated tablets is 90-100%. No first-pass effect was observed. The mean elimination half-life is 3 to 4 hours.
Lornoxicam is found in the plasma in unchanged form and as its hydroxylated metabolite. The hydroxylated metabolite exhibits no pharmacological activity.
The plasma protein binding of lornoxicam is 99% and not concentration dependent.
Lornoxicam is metabolized completely, and approximately 2/3 is eliminated via the liver and 1/3 via the kidneys as inactive substance.
Lornoxicam is metabolized by cytochrome P450 2C9. Due to genetic polymorphism slow and rapid metabolisers exist for this drug, which could result in markedly increased plasma levels of lornoxicam in slow metabolisers.
Simultaneous intake of lornoxicam with meals reduced Cmax by approximately 30%. Tmax was increased from 1,5 to 2,3 hours. The absorption of lornoxicam (calculated on AUC) can be reduced up to 20%.
Simultaneous intake with antacids has no effect on the pharmacokinetics of lornoxicam.
In elderly subjects the clearance is reduced by 30 to 40%. Apart from this reduced clearance there is no significant change in the kinetic profile of lornoxicam in elderly patients, or in patients with mild hepatic or kidney dysfunction.
Paracetamol (acetaminophen) is a pain reliever and a fever reducer. The exact mechanism of action of is not known.Paracetamol is used to treat many conditions such as headache, muscle aches, arthritis, backache, toothaches, colds, and fevers. It relieves pain in mild arthritis but has no effect on the underlying inflammation and swelling of the joint.
- Minimum Order Quantity: 20 Packs